CN116135884A - 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途 - Google Patents

抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途 Download PDF

Info

Publication number
CN116135884A
CN116135884A CN202111359665.8A CN202111359665A CN116135884A CN 116135884 A CN116135884 A CN 116135884A CN 202111359665 A CN202111359665 A CN 202111359665A CN 116135884 A CN116135884 A CN 116135884A
Authority
CN
China
Prior art keywords
tigit
antibody
ser
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111359665.8A
Other languages
English (en)
Chinese (zh)
Inventor
戴爽
翟天航
黄威峰
彭绍岗
孙左宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotheus Inc
Original Assignee
Biotheus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheus Inc filed Critical Biotheus Inc
Priority to CN202111359665.8A priority Critical patent/CN116135884A/zh
Priority to US18/711,482 priority patent/US20250019436A1/en
Priority to AU2022389530A priority patent/AU2022389530A1/en
Priority to JP2024529415A priority patent/JP2024542192A/ja
Priority to CA3238571A priority patent/CA3238571A1/en
Priority to CN202280075442.5A priority patent/CN118251419A/zh
Priority to EP22894869.1A priority patent/EP4435010A4/en
Priority to PCT/CN2022/132422 priority patent/WO2023088337A1/zh
Priority to KR1020247019886A priority patent/KR20240103034A/ko
Publication of CN116135884A publication Critical patent/CN116135884A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202111359665.8A 2021-11-17 2021-11-17 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途 Pending CN116135884A (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN202111359665.8A CN116135884A (zh) 2021-11-17 2021-11-17 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
US18/711,482 US20250019436A1 (en) 2021-11-17 2022-11-17 Bispecific Antibody against TIGIT and PD-L1, and Pharmaceutical Composition Thereof and Use Thereof
AU2022389530A AU2022389530A1 (en) 2021-11-17 2022-11-17 Bispecific antibody against tigit and pd-l1, and pharmaceutical composition thereof and use thereof
JP2024529415A JP2024542192A (ja) 2021-11-17 2022-11-17 Ｔｉｇｉｔおよびｐｄ－ｌ１に対する二重特異性抗体、ならびにその医薬組成物およびその使用
CA3238571A CA3238571A1 (en) 2021-11-17 2022-11-17 Bispecific antibody against tigit and pd-l1, and pharmaceutical composition thereof and use thereof
CN202280075442.5A CN118251419A (zh) 2021-11-17 2022-11-17 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
EP22894869.1A EP4435010A4 (en) 2021-11-17 2022-11-17 Bispecific antibody against TIGIT and PD-L1, its pharmaceutical composition and use
PCT/CN2022/132422 WO2023088337A1 (zh) 2021-11-17 2022-11-17 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
KR1020247019886A KR20240103034A (ko) 2021-11-17 2022-11-17 Tigit 및 pd-l1에 대한 이중특이적 항체, 그의 의약 조성물, 및 그의 용도

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111359665.8A CN116135884A (zh) 2021-11-17 2021-11-17 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途

Publications (1)

Publication Number Publication Date
CN116135884A true CN116135884A (zh) 2023-05-19

Family

ID=86332938

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111359665.8A Pending CN116135884A (zh) 2021-11-17 2021-11-17 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
CN202280075442.5A Pending CN118251419A (zh) 2021-11-17 2022-11-17 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202280075442.5A Pending CN118251419A (zh) 2021-11-17 2022-11-17 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途

Country Status (8)

Country Link
US (1) US20250019436A1 (https=)
EP (1) EP4435010A4 (https=)
JP (1) JP2024542192A (https=)
KR (1) KR20240103034A (https=)
CN (2) CN116135884A (https=)
AU (1) AU2022389530A1 (https=)
CA (1) CA3238571A1 (https=)
WO (1) WO2023088337A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025045190A1 (zh) * 2023-08-31 2025-03-06 江苏恒瑞医药股份有限公司 Ctla4/tigit结合蛋白及其医药用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202544031A (zh) * 2024-02-29 2025-11-16 南韓商柳韓洋行股份有限公司 抗tigit/抗pd-l1雙特異性抗體及其用途
CN117924510B (zh) * 2024-03-21 2024-06-04 北京星基贝勤生物科技有限公司 靶向egfr和axl的双特异性抗体及其药物偶联物与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA2994858C (en) * 2015-09-25 2024-01-23 Genentech, Inc. Anti-tigit antibodies and methods of use
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
CN112480253B (zh) * 2019-09-12 2022-09-20 普米斯生物技术(珠海)有限公司 一种抗pd-l1纳米抗体及其衍生物和用途
CN113461824A (zh) * 2020-03-31 2021-10-01 普米斯生物技术(珠海)有限公司 一种构建多特异性抗体的平台
CN117794952A (zh) * 2021-08-09 2024-03-29 普米斯生物技术(珠海)有限公司 抗tigit抗体及其用途
CN116925222A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗pvrig抗体、其药物组合物及用途
CN116925233A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025045190A1 (zh) * 2023-08-31 2025-03-06 江苏恒瑞医药股份有限公司 Ctla4/tigit结合蛋白及其医药用途

Also Published As

Publication number Publication date
WO2023088337A1 (zh) 2023-05-25
CA3238571A1 (en) 2023-05-25
KR20240103034A (ko) 2024-07-03
US20250019436A1 (en) 2025-01-16
EP4435010A4 (en) 2025-11-19
CN118251419A (zh) 2024-06-25
JP2024542192A (ja) 2024-11-13
EP4435010A1 (en) 2024-09-25
AU2022389530A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
US12234286B2 (en) Anti-TIGIT antibodies and their use as therapeutics and diagnostics
RU2739610C1 (ru) Антитело против PD-1 и его применение
JP7425604B2 (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
US20210340239A1 (en) Anti-pd-1/vegfa bifunctional antibody, pharmaceutical composition thereof and use thereof
EP4435010A1 (en) Bispecific antibody against tigit and pd-l1, and pharmaceutical composition thereof and use thereof
CN114478769B (zh) 抗tigit抗体、其药物组合物及用途
EP4506365A1 (en) Anti-tigit/anti-pvrig bispecific antibody, and pharmaceutical composition and use thereof
EP4506360A1 (en) Anti-pvrig antibody, pharmaceutical composition thereof and use thereof
CA3228137A1 (en) Cldn18.2-targeting antibody, bispecific antibody and use thereof
WO2023241656A1 (zh) 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途
JP2024532836A (ja) 抗ＴＩＧＩＴ抗体及びＴＧＦ－βＲを含む融合タンパク質、並びにその医薬組成物及び使用
JP2026508210A (ja) ＴＧＦ－βＲＩＩ細胞外領域断片を含む融合タンパク質、その医薬組成物、およびその使用
AU2024341649A1 (en) Pharmaceutical combination and use
HK40093009A (en) Anti-tigit antibody, and pharmaceutical composition and use thereof
EA049283B1 (ru) Антитело к tigit и его фармацевтическая композиция и применение
EA042365B1 (ru) Бифункциональное антитело против ctla4 и против pd-1, его фармацевтическая композиция и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230519